- Home
- PAYS vs DAWN Comparison
PAYS vs DAWN Comparison
Compare PAYS & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYS
- DAWN
- Stock Information
- Founded
- PAYS 2001
- DAWN 2018
- Country
- PAYS United States
- DAWN United States
- Employees
- PAYS N/A
- DAWN N/A
- Industry
- PAYS Business Services
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- PAYS Consumer Discretionary
- DAWN Health Care
- Exchange
- PAYS Nasdaq
- DAWN Nasdaq
- Market Cap
- PAYS 125.2M
- DAWN 624.8M
- IPO Year
- PAYS 1998
- DAWN 2021
- Fundamental
- Price
- PAYS $5.73
- DAWN $7.18
- Analyst Decision
- PAYS Strong Buy
- DAWN Strong Buy
- Analyst Count
- PAYS 4
- DAWN 7
- Target Price
- PAYS $7.31
- DAWN $27.86
- AVG Volume (30 Days)
- PAYS 728.1K
- DAWN 999.9K
- Earning Date
- PAYS 11-04-2025
- DAWN 10-29-2025
- Dividend Yield
- PAYS N/A
- DAWN N/A
- EPS Growth
- PAYS N/A
- DAWN N/A
- EPS
- PAYS 0.12
- DAWN N/A
- Revenue
- PAYS $68,539,381.00
- DAWN $187,638,000.00
- Revenue This Year
- PAYS $35.12
- DAWN $12.56
- Revenue Next Year
- PAYS $20.99
- DAWN $48.02
- P/E Ratio
- PAYS $47.84
- DAWN N/A
- Revenue Growth
- PAYS 27.84
- DAWN 2190.50
- 52 Week Low
- PAYS $1.80
- DAWN $5.64
- 52 Week High
- PAYS $8.88
- DAWN $16.76
- Technical
- Relative Strength Index (RSI)
- PAYS 53.06
- DAWN 51.39
- Support Level
- PAYS $5.08
- DAWN $7.03
- Resistance Level
- PAYS $5.48
- DAWN $7.58
- Average True Range (ATR)
- PAYS 0.25
- DAWN 0.28
- MACD
- PAYS 0.10
- DAWN -0.04
- Stochastic Oscillator
- PAYS 82.29
- DAWN 30.80
About PAYS Paysign Inc.
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.